Many parents are frustrated with the current reality that the regular stimulant medication for their child with Attention Deficit Hyperactivity Disorder (ADHD) is out of stock at local pharmacies. The reasons underlying this shortage are complex and multifactorial.
The COVID-19 pandemic altered the supply chain for ADHD medications and resulted in shortages in a market that was already tightly restricted. Because of the suspension in January 2020 of the Ryan Haight Online Pharmacy Consumer Protection Act of 2008, the total number of psychostimulant prescriptions rose by 10% among American adolescents and adults. Of note, the Ryan Haight Act tightly regulated the ability of telepsychiatry providers to prescribe controlled substances. In addition, certain companies are taking aim at individuals for whom ADHD medications are not indicated. Former U.S. government lawyers/employees have denounced some start-ups for prioritizing profit over patient well-being.
Despite awareness of a shortfall in psychostimulant supplies since 2021, U.S. regulators have been slow to react. Although the FDA has announced plans to update boxed warnings to mitigate misuse by patients and prescribers, this step will not alleviate the supply issues.
What steps can be taken to mitigate the short supply and provide increased access to psychostimulants to children with ADHD?
-
Robert Kass2yrThe supply problem is not limited to ADHD medications. I do not know all of the factors behind this, but I think there needs to be more domestic production Show More -
Amy Gonzales, Physician2yrFirstly, we have to make sure that we are screening and diagnosing patients appropriately for ADHD. Lots of medical conditions can mask or occur concurrently with ADHD. Sadly, lots of Show More
